Yugawa et al. (2021) reported that CMTM6 stabilizes PD-L1 expression and is a new prognostic impact factor in hepatocellular carcinoma. Zhang, Zhao & Wang (2021) indicated that high CMTM6 expression correlated with a poor prognosis in gastric cancer patients. The role of CMTM6 in colorectal cancer is opposite to that in liver cancer and gastric cancer. Peng et al. (2021) found that CMTM6 is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. The gene discussed is CD274; the disease is hepatocellular carcinoma.